Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity

Journal of Medicinal Chemistry

Volumn 51, Issue 11, 2008, Pages 3297-3303

  Nakagawa Goto, Kyoko ^a   Bastow, Kenneth F ^a   Chen, Tzu Hsuan ^a   Morris Natschke, Susan L ^a   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (NAPHTHALEN 1 YL)DESMOSDUMOTIN B; 2 (NAPHTHALEN 1' YL) 6,8,8 TRIETHYLDESMOSDUMOTIN B; 2' METHYLDESMOSDUMOTIN B; 2',4',6' TRIMETHYLDESMOSDUMOTIN B; 3',5' DIMETHYLDESMOSDUMOTIN B; 4' ETHYLDESMOSDUMOTIN B; 4' METHYLDESMOSDUMOTIN B; 6 ETHYL 8,8 DIMETHYLDESMOSDUMOTIN B; 6,8 DIETHYL 2 (4 ETHYLPHENYL) 5,7 DIHYDROXYCHROMEN 4 ONE; 6,8,8 TRIETHYL 2 (PHENANTHREN 9' YL)DESMOSDUMOTIN B; 6,8,8 TRIETHYL 2' METHYLDESMOSDUMOTIN B; 6,8,8 TRIETHYL 4' ETHYLDESMOSDUMOTIN B; 6,8,8 TRIETHYL 4' METHYLDESMOSDUMOTIN B; 6,8,8 TRIETHYL 5 HYDROXY 3 PHENYL 4H CHROMENE 4,7(8H) DIONE; 6,8,8 TRIETHYLDESMOSDUMOTIN B; 6,8,8 TRIPROPYLDESMOSDUMOTIN B; ANTINEOPLASTIC AGENT; DESMOSDUMOTIN B DERIVATIVE; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYCLIZATION; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONES; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44949185446     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701208v     Document Type: Article

References (32)

1. Fojo, T.; Bates, S. Strategies for reversing drug resistance. Oncogene 2003, 22, 7512-7523.
2. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94, 15-21.
3. Ambudkar, S. V; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22, 7468-7485.
4. Leonard, G. D.; Fojo, T.; Bates, S. The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411-424.
5. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer, role of ATP-dependent transporter. Nat. Rev. Can. 2002, 2, 48-58.
6. Litman, T.; Druley, T. E.; Stein, W. D.; Bates, S. E. From MDR to MXR: new understanding of multidrug resistance system, their properties in clinical significance. Cell. Mol. Life Sci. 2001, 58, 931-959.
7. Sawicka, M.; Kalinowska, M.; Skierski, J.; Lewandowski, W. A review of selected antitumor therapeutic agents and reasons for multidrug resistance occurrence. J. Pharm. Pharmacol. 2004, 56, 1067-1087.
8. Endicott, J. A.; Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989, 58, 137-171.
9. Cole, S. P.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
10. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
11. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001, 167, 3-23.
12. Holland, B.; Cole, S. P. C.; Kuchler, K.; Higgins, C. F., Eds. ABC Protein from Bacteria to Man; Academic Press: San Diego, 2003.
13. Takara, K.; Sakaeda, T.; Okumura, K. An update on overcoming MDRl-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 2006, 12, 273-286.
14. Modok, S.; Mellor, H. R.; Callaghan, R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharm. 2006, 6, 350-354.
15. Avendaño, C.; Menéndez, C. Recent advances in multidrug resistance modulators. Med. Chem. Rev. 2004, 1, 419-444.
16. Lehne, G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets 2000, 1, 85-99.
17. Boumendjel, A.; Baubichon-Cortay, H.; Trompier, D.; Perrotton, T.; Di Pietro, A. Anticancer multidrug resistance mediated by MRP1: Recent advances in the discovery of reversal agents. Med. Res. Rev. 2005, 25, 453-472.
18. Mavel, S.; Dikic, B.; Palakas, S.; Emond, P.; Greguric, I.; Gracia, A. G.; Mattner, F.; Garrigos, M.; Guilloteau, D.; Katsifis, A. Synthesis and biological evaluation of a series of flavone derivatives as potential radioligands for imaging the multidrug resistance-associated protein 1 (ABBCC1/MRP1). Bioorg. Med. Chem. 2006, 14, 1599-1607.
19. Boumendjel, A.; Pietro, A. D.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev. 2002, 22, 512-529.
20. Wet, H.; McIntosh, D. B.; Conseil, G.; Baubichon-Cortay, H.; Krell, T.; Jault, J. M.; Daskiewicz, J. B.; Barron, D.; Pietro, A. D. Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein: Structure-activity relationships for flavonoid binding. Biochemistry 2001, 40, 10382-10391.
21. Wu, J.-H.; Mao, S. L.; Liao, S. X.; Yi, Y. H.; Lan, C. Q.; Su, Z. W. Desmosdumotin B: A new special flavone from Desmos dumosus. Chin. Chem. Lett. 2001, 12, 49-50.
22. Wu, J.-H; McPhail, A. T.; Bastow, K. F.; Shiraki, H.; Ito, Junko; Lee, K.-H. Desmosdumotin C, a novel cytotoxic principle from Desmos dumosus. Tetrahedron Lett. 2002, 43, 1391-1393.
23. Nakagawa-Goto, K.; Bastow, K. F.; Wu, J.-H.; Tokuda, H.; Lee, K. H. Total synthesis and bioactivity of unique flavone desmosdumotin B and its analogs. Bioorg. Med. Chem. Lett. 2005, 15, 3016-3019.
24. Nakagawa-Goto, K.; Wu, J.-H; Lee, K.-H. First total synthesis of desmosdumotin C. Synth. Commun. 2005, 35, 1-5.
25. Nakagawa-Goto, K.; Wu, J.-H.; Bastow, K. F.; Wu, C.-C.; Lee, K. H. Antitumor agents 243. Syntheses and cytotoxicity of desmosdumotin C derivatives. Bioorg. Med. Chem. 2005, 13, 2325-2330.
26. Nakagawa-Goto, K.; Chen, T.-H.; Peng, C.-Y.; Bastow, K. F.; Lee, K. H. Antitumor agents 259. Design, syntheses and structure-activity relationship study of desmosdumotin C analogues. J. Med. Chem. 2007, 50, 3354-3358.
27. Balasubramanian, S.; Nair, G. M. An efficient "one pot" synthesis of isoflavones. Synth. Commun. 2000, 30, 469-484.
28. 2,6-Dimethyl-DesB showed similar activity and selectivity against KB and KB-VIN to 2,4,6-trimethyl-DesB (6), although the data were not shown because of the low yield and difficulty of purification of this compound.
29. Ishikawa, T.; Onishi, Y.; Hirano, H.; Oosumi, K.; Nagakura, M.; Tarui, S. Pharmacogenomics of drug transporters: a new approach to functional analysis of ABCB1 (P-glycoprotein/MDR1). Biol. Pharm. Bull. 2004, 27, 939-948.
30. Kimchi-Sarfaty, C.; Oh, J. M.; Kim, I. W.; Sauna, Z. E.; Calcagno, A. M.; Ambudkar, S. V.; Gottesman, M. M. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 26, 525-528.
31. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nature Rev. 2006, 6, 813-823.
32. Ludwig, J. A.; Szakács, G.; Martin, S. E.; Chu, B. F.; Cardarelli, C.; Sauna, Z. E.; Caplen, N. J.; Fales, H. M.; Ambudkar, S. V.; Weinstein, J. N.; Gottesman, M. M. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 2006, 66, 4808-4815.